Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Improving outcome in subarachnoid hemorrhage with nadroparin (ISCHEMIA)
2024-511679-14-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2024
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of nadroparin in subarachnoid hemorrhage (SAH), sponsored by Amsterdam University Medical Center. Primary endpoint: 30-day mortality. Planned start Aug 2024; status: authorised.
02
Drugs
nadroparin
03
Conditions
subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on 2024-511679-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511679-14-00.